Clinical outcomes after initial treatment of methicillin-resistant Staphylococcus aureus infections.

ABSTRACT:

Objective

To evaluate the clinical outcomes associated with anti-methicillin-resistant Staphylococcus aureus (MRSA) antimicrobials.

Methods

We reviewed a prospective database of 247 consecutive patients with clinically and microbiologically confirmed MRSA infections, hospitalized in 7 Japanese hospitals between April 2014 and March 2015, and treated with anti-MRSA pharmaceuticals. Survival was measured at 30 days. We examined the relationships between initial antimicrobial administered and survival and organ toxicity. HR and 95% CIs were calculated.

Results

Overall 30-day mortality was 12%. The lungs were infected in 105 (41%), skin and soft tissue in 73 (30%), and bones and joints in 21 (9%) patients. Bacteremia complicated the illness in 69 patients (28%). Am

SUBMITTER: Shime N 

PROVIDER: S-EPMC6084090 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature